Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Promimic AB (publ) in connection with its listing on Nasdaq First North Growth Market
Mandate

Vinge has advised Promimic AB (publ) in connection with its listing on Nasdaq First North Growth Market

April 29, 2022 Capital Markets and Public M&A

Vinge has advised Promimic AB (publ) in connection with its listing on Nasdaq First North Growth Market. The first day of trading is 29 April 2022. In connection with the listing, a shares subscription offer was performed at a subscription price of SEK 16.

Promimic AB is a biomaterials company which produces and markets HAnano Surface, a unique coating for medical implants which strengthens their anchoring in bone tissue. Promimic focuses on the dental and orthopaedic implant market.

Vinge’s team consisted primarily of Anders Strid, Johanna Hamrefält (project manager), Adrian Filipovic, Rebecka Hansson, Anna Högsten and Fredrik Löwenclou.

 

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025